Programme Thesis
The EIC Accelerator Open provides non-dilutive grant funding (up to €2.5M) and equity investments (up to €15M) to high-risk, deep-tech startups and SMEs developing breakthrough innovations with significant market-creating potential. It exists to bridge the funding gap for technologies that are too risky for private investors but have the potential to scale globally and create new markets, particularly in strategic areas like health, AI, and sustainability.
Selection Criteria
Eligibility: SME (including single-person startup) registered in EU or Horizon Europe associated country; or natural person willing to incorporate in EU. Scoring rubric (out of 15): 1) Breakthrough/Deep Tech (5 pts) – novelty, scientific excellence, proof-of-concept; 2) Market Creation & Impact (5 pts) – scalability, EU strategic autonomy, job creation; 3) Team & Commercial Pathway (5 pts) – entrepreneurial capacity, go-to-market plan, IP strategy. Reviewer priorities: clear technological differentiation, validated prototype (TRL 5-6), credible commercialisation roadmap, strong team (or plan to build one), and alignment with EU policy goals (e.g., digital health, green transition).
Past Winners / Cohort Profiles
Past winners are typically deep-tech startups with a patented or patent-pending core technology, often spun out from universities or research institutes. Examples include: 1) Neuroelectrics (Spain) – non-invasive brain stimulation for neurological disorders; 2) TreeFrog Therapeutics (France) – stem-cell manufacturing platform; 3) Iktos (France) – AI-driven drug discovery. Archetypes: pre-revenue or early-revenue, 2-5 years old, strong scientific advisory board, and a clear plan to reach market within 2-3 years post-funding.
Ideal Candidate Fingerprint
The platonic ideal applicant is a deep-tech startup (or natural person) with a patented breakthrough technology at TRL 5-6, a validated proof-of-concept in a relevant environment, and a credible plan to scale into a new market. They have a balanced team combining scientific expertise and business acumen, a clear IP strategy, and a compelling narrative of how their innovation creates EU strategic autonomy or addresses a major societal challenge.
Recommended Framing
Eniola should position the CCT model as a breakthrough deep-tech platform for addiction treatment, emphasising its validated proof-of-concept (85.8% reduction in encoding probability, super-additivity confirmed) and its potential to create a new market in precision addiction therapeutics. Highlight the provisional patent, the endorsements from leading neuroscientists (Berridge, Gershman, Daw), and the planned partnerships with Servier and Paris-Saclay to demonstrate commercial traction and EU alignment. Frame the venture as a pre-seed AI/biotech company (ZYCO) that will use the EIC funding to advance to TRL 6, conduct a Phase I/IIa clinical trial, and build a team around the CCT platform.
Watch Out
1) Eniola is currently an independent researcher based in Nigeria, not an EU-registered SME or natural person with EU residency – he must incorporate a company in an EU member state (e.g., France via Paris-Saclay partnership) before applying. 2) The programme typically funds startups with a team; as a solo founder, he will need to demonstrate a credible plan to recruit a CEO/COO and business development lead. 3) The technology is at TRL 3-4 (validated in silico), but the EIC Accelerator expects TRL 5-6 (validated in relevant environment) – he should plan to generate in vivo or clinical pilot data before the deadline.